Johnson & Johnson Delivers Bright Q2 Results, Revenue and Profit Both Beat Expectations and Guidance Raised, Pre-Market Shares Fall Against Trend

TradingKey - On Wednesday local time, global healthcare giant Johnson & Johnson ( JNJ) released its second-quarter 2026 financial results, with both revenue and earnings beating market expectations. Meanwhile, management further raised its full-year guidance, once again demonstrating its robust growth capabilities in its two major business segments: innovative medicine and medical technology.

However, the company's shares fell over 2% in pre-market trading following the earnings release. Nonetheless, looking at its full-year performance, Johnson & Johnson's stock price has maintained strong resilience. Year-to-date, the stock has accumulated a gain of approximately 22%, significantly outperforming the S&P Global 100 Index's gain of about 8.2% over the same period.

Source: TradingView

Revenue and Profit Both Beat Market Expectations

Looking at this quarter's results, Johnson & Johnson sustained its steady growth momentum. The company reported second-quarter revenue of $25.31 billion, beating market consensus of $25.02 billion, up approximately 6.6% from $23.74 billion in the same period last year; adjusted earnings per share reached $2.90, also topping analysts' expectations of $2.86.

Along with the better-than-expected second-quarter performance, management also raised its full-year earnings guidance. The company now expects 2025 adjusted earnings per share to be between $11.60 and $11.75, with a midpoint of approximately $11.68, higher than the previous market estimate of $11.58.

Meanwhile, the company expects full-year revenue to be between $100.8 billion and $101.4 billion, with a midpoint of approximately $101.1 billion, which is also slightly above market consensus, showing that management remains optimistic about its business performance in the coming quarters.

Joaquin Duato, Chairman and Chief Executive Officer of Johnson & Johnson, said that the company's second-quarter results reflect the ongoing translation of innovative R&D into commercial outcomes, while the diverse product portfolio and advancing pipeline provide a solid foundation for future growth. The company will continue to drive the development of innovative therapies in major disease areas to meet growing global healthcare needs.

Innovative Pharmaceuticals Become Core Growth Driver

By business segment, the Innovative Medicine business was the primary growth driver for Johnson & Johnson this quarter, with worldwide operational sales increasing by 6.8%.

Among them, DARZALEX, CARVYKTI, TECVAYLI, and RYBREVANT in oncology, TREMFYA in immunology, and SPRAVATO and CAPLYTA in neuroscience all delivered outstanding performances, serving as the core drivers of growth.

However, sales declines for STELARA and REMICADE exerted some drag on overall growth, reflecting that the company still faces certain pressures in navigating patent cliff challenges.

The MedTech business segment recorded operational sales growth of 3.6%, primarily driven by wound closure products, biosurgery products, electrophysiology products, and the Shockwave business. This growth performance was in line with market expectations and also demonstrated Johnson & Johnson's continuous innovation capabilities and market competitiveness in the medical technology field.